Search Results - "ФАРМАКОЛОГИЧЕСКОЕ ИССЛЕДОВАНИЕ"

1

Academic Journal

The effect of anxiolytic drug afobazole on the quality of life of patients with anxiety disorders

Authors: O. A. Dorofeeva, M. V. Metlina, S. A. Siuniakov, G. G. Neznamov

Source: Качественная клиническая практика, Vol 0, Iss 2, Pp 57-63 (2018)

Subject Terms: тревожные расстройства, качество жизни, анксиолитическое средство, афобазол, клинико-фармакологическое исследование, anxiety disorders, quality of life, anxiolytic, fabomotizole, clinical and pharmacological research, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/48; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

Access URL: https://doaj.org/article/edc35991eb4342ebbab107373e4186c9

View record in DOAJ

2

Academic Journal

The effect of anxiolytic drug afobazole on the quality of life of patients with anxiety disorders ; Влияние анксиолитика афобазола на качество жизни больных с тревожными расстройствами

Authors: O. A. Dorofeeva, M. V. Metlina, S. A. Siuniakov, G. G. Neznamov, О. А. Дорофеева, М. В. Метлина, С. А. Сюняков, Г. Г. Незнамов

Source: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 2 (2016); 57-63 ; Качественная клиническая практика; № 2 (2016); 57-63 ; 2618-8473 ; 2588-0519

Subject Terms: clinical and pharmacological research, качество жизни, анксиолитическое средство, афобазол, клинико-фармакологическое исследование, anxiety disorders, quality of life, anxiolytic, fabomotizole

File Description: application/pdf

Relation: https://www.clinvest.ru/jour/article/view/48/48; Bowling A. Measuring health: a review of quality of life measurement scales. // Maidenhead: Open University Press. 2004; 224.; Ritsner M.S., Awad A.G. Quality of life impairmentin schizophrenia, mood and anxiety disorders: new perspectives on research and treatment. // New York: Springer, 2007; 388.; WHOQOL Group. The development of Life assessment instrument (the WHOQOL). In: Orley J., Kuyken W. (eds). Quality of Life assessment: international perspectives. // Berlin - Heidelberg: Springer Verlag, 1994;.41-57.; Тиганов А.С. Круглый стол. Качество жизни: методологические проблемы и перспективы исследования / А.С.Тиганов // Психические расстройства и сердечно-сосудистая патология. - М., 1994. - С. 166-180.; Незнанов Н.Г., Иванов М.В., Мазо Г.Э. и др. Динамика показателей качества жизни больных шизофренией в процессе лечения рисполептом // Психиатрия и психофармакотерапия. 2002; 5: 194-195.; Середенин С.Б., Воронина Т. А., Незнамов Г.Г. и соавт. / Фармакогенетическая концепция анксиолитического эффекта. // Вестник АМН, 1998; 11: 47-52.; Середенин С.Б., Воронин М.В. Нейрорецепторные механизмы действия Афобазола // Экспериментальная и клиническая фармакология. 2009; 1: 3-11.; Александровский Ю.А., Руденко Г.М., Незнамов Г.Г. и др.- Унифицированная система оценки клинико-фармакологического действия психотропных препаратов у больных с пограничными нервно-психическими расстройствами. // М.: 1984; 69.; Hamilton M. - The assesment of anxiety states by rating. // Br. Soc. Med. Psychol. 32:1959; 50-55.; Smets E.M.A., Garssen, Bonke J.C., J. M. De Haes. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. // Journal of psychosomatic research, 1995: 39: 5: 315-325.; Miller M.D., Ferris D.G. Measurement of subjective phenomenain primary care research: the visual analogue scale. // Fam Pract ResJ, 1993; 13: 15-24.; National Institute of Mental Health: 12- CGI. Clinical Global Impression // W.Guyo (Ed.). ECDEU Assesment Manual for Psychopharmacology. Rev. Ed. Rockville, Maryland, 1976; 217-222.; WHOQOL Group (1998). Development of World Health Organization WHOQOL-Bref quality of life assessment. // Psychl Med; 28: 551-558.; Незнамов Г.Г., Сюняков С.А., Чумаков Д.В., Маметова Л.Э. Новый селективный анксиолитик афобазол. // Журн. неврологии и психиатрии им. С.С.Корсакова. 2005; 105: 4: 48-54.; Незнамов Г.Г., Сюняков С.А., Чумаков Д.В. и др. Результаты клинического изучения селективного анксиолитика афобазола // Экспериментальная клиническая фармакология. М.: 2001; 64: 2: 15-19.; Spitzer R. Health related qualitu of life in patients with mental disorders according to research in primary care II / Spitzer R., Kroenke K., Linzer M. // JAMA. 1995; 274: 1511 - 1517.; Незнамов Г.Г., Сюняков С.А., Чумаков Д.В., Телешова Е.С. и др. Новый анксиолитик афобазол: результаты сравнительного клинического исследования с диазепамом при генерализованном тревожном расстройстве // Психиатрия и психофармакотерапия. 2006; 8: 4: 8-13.; https://www.clinvest.ru/jour/article/view/48

Availability: https://www.clinvest.ru/jour/article/view/48

View record from BASE

3

Academic Journal

MODERN PARADIGM OF THE PREGNANT-INVOLVING PHARMACOLOGICAL STUDY: RISK ASSESSMENT, ETHICAL PRINCIPLES AND REGULATORY ASPECT ; СОВРЕМЕННАЯ ПАРАДИГМА ФАРМАКОЛОГИЧЕСКОГО ИССЛЕДОВАНИЯ С УЧАСТИЕМ БЕРЕМЕННЫХ ЖЕНЩИН: ОЦЕНКА РИСКА, МОРАЛЬНО-ЭТИЧЕСКИЕ ПРИНЦИПЫ И РЕГУЛЯТОРНЫЙ АСПЕКТ

Authors: K. A. Lutsevich, O. V. Reshetko, T. S. Lutsevich, К. А. Луцевич, О. В. Решетько, Т. С. Луцевич

Source: Pediatric pharmacology; Том 11, № 2 (2014); 22-29 ; Педиатрическая фармакология; Том 11, № 2 (2014); 22-29 ; 2500-3089 ; 1727-5776

Subject Terms: регуляторный процесс, pharmacological study, ethics, regulatory process, фармакологическое исследование, этика

File Description: application/pdf

Relation: https://www.pedpharma.ru/jour/article/view/115/129; https://www.pedpharma.ru/jour/article/view/115/130; Lyerly A. D., Little M. O., Faden R. The second wave: Toward responsible inclusion of pregnant women in research. Int J Fem Approaches Bioeth. 2008; 1 (2): 5–22.; Завидова С. С., Тополянская С. В., Намазова-Баранова Л. С. Клинические исследования лекарственных препаратов в педиатрии: проблемы и достижения. Педиатрическая фармакология. 2010; 7(1):6-14.; Dunlop A. L., Gardiner P. M., Shellhaas C. S. et al. The clinical content of preconception care: the use of medications and supplements among women of reproductive age. Am J Obstet Gynecol. 2008; Supplement to December: S367–372.; Koren G. Pharmacokinetics in pregnancy; clinical significance. J Popul Ther Clin Pharmacol. 2011; 18: e523–527.; Parisi M. A., Spong C. Y., Zajicek A., Guttmacher A. E. We don't know what we don't study: the case for research on medication effects in pregnancy. Am J Med Genet C Semin Med Genet. 2011; 157: 247–250.; Giacoia G., Mattison D. Obstetric and Fetal Pharmacology. Glob libr women's med (ISSN: 1756–2228). 2009.; McCullough L. B., Coverdale J. H., Chervenak F. A. A com pre hensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. Am J Obstet Gynecol. 2005; 193: 901–907.; Longo L. D., Jaffe R. B. A challenge for the 21st century: whither physician-scientists in obstetrics, gynecology, and the reproductive sciences? Am J Obstet Gynecol. 2008; 198: 489–495.; Horgan R. P., Clancy O. H., Myers J. E., Baker P. N. An overview of proteomic and metabolomic technologies and their application to pregnancy research. BJOG. 2009; 116: 173–181.; Wilffert B., Altena J., Tijink L. et al. Pharmacogenetics of drug-induced birth defects: what is known so far? Pharmacogenomics. 2011; 12: 547–558.; Dominguez V., Ramos N., Torrents A. et al. Clinical trials during pregnancy: what has been done. Eur J Clin Pharmacol. 2012; 68: 455–458.; Koren G. Is it appropriate to study the pharmacokinetics of drugs aimed at pregnant women in men? J Obstet Gynaecol Can. 2010; 32: 629–630.; Uhl K., Parekh A., Kweder S. Females in clinical studies: where are we going? Clin Pharmacol Ther. 2007; 81: 600–602.; Anderson G. D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharma-cokinetics, and pharmacodynamics. J Women’s Health. 2005; 14: 19–29.; Chen M. L., Lee S. C., Ng M. J. et al. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 2000; 68: 510–521.; Bourget P., Roulot C., Fernandez H. Models for placental transfer studies of drugs. Clin Pharmacokinet. 1995; 28: 161–180.; Gedeon C., Nava-Ocampo A. A., Koren G. Ethical issues in pharmacologic research in women undergoing pregnancy termination: a systemic review and survey of researchers. Obstet Gynecol Int. 2012; 2012: 724591.; Anderson F., Glasier A., Ross J., Baird D. T. Attitudes of women to fetal tissue research. J Med Ethics. 1994; 20: 36–40.; Goldkind S. F., Sahin L., Gallauresi B. Enrolling pregnant women in research — lessons from the H1N1 influenza pandemic. N Engl J Med. 2010; 362: 2241–2243.; Hines R. N., Sargent D., Autrup H. et al. Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population. Toxicol Sci. 2010; 113: 4–26.; Иванова А. А., Михайлов А. В., Колбин А. С. Тератогенные свойства лекарств. История вопроса. Педиатрическая фармакология. 2013; 10 (1): 46–53.; Шер С. А. Тератогенное воздействие лекарственных средств на организм будущего ребенка на этапе внутриутробного развития. Педиатрическая фармакология. 2011; 8 (6): 57–60.; Jelinek R. The contribution of new findings and ideas to the old principles of teratology. Reprod Toxicol. 2005; 20: 295–300.; Widmer N., Meylan P., Ivanyuk A. et al. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin Pharmacokinet. 2010; 49: 741–765.; Beigi R. H., Han K., Venkataramanan R. et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol. 2011; 204 (6 Suppl.): 84–88.; Greer L. G., Leff R. D., Rogers V. L. et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol. 2011; 204 (6 Suppl.): 89–93.; Andrew M. A., Easterling T. R., Carr D. B. et al. Amoxicillin pharmacokinetics in pregnant women: Modeling and simulations of dosage strategies. Clin Pharmacol Ther. 2007; 81: 547–556.; Hebert M. F., Ma X., Naraharisetti S. B. et al. Are we optimizing gestational diabetes treatment with glyburide the pharmacologic basis for better clinical practice? Clin Pharmacol Ther. 2009; 85: 607–614.; Langer O., Conway D. L., Berkus M. D. et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000; 343: 1134–1138.; Rowan J. A., Hague W. M., Gao W. et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008; 358: 2003–2015.; Eyal S., Easterling T. R., Carr D. et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos. 2010; 38: 833–840.; Roberts J. M., Hubel C. A. The two stage model of preeclampsia: variations on the theme. Placenta. 2009; 30 (Suppl.): 32–37.; Hogstedt S., Lindberg B., Peng D. R. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther. 1985; 37: 688–692.; Hogstedt S., Rane A. Plasma concentration-effect relationship of metoprolol during and after pregnancy. Eur J Clin Pharmacol. 1993; 44: 243–246.; Hebert M. F., Carr D. B., Anderson G. D. et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol. 2005; 45: 25–33.; McDonald K., Amir L. H., Davey M. A. Maternal bodies and medicines: a commentary on risk and decision-making of pregnant and breastfeeding women and health professionals. BMC Public Health. 2011; 11 (Suppl. 5): S5.; Решетько О. В., Луцевич К. А. Рейтинговые системы фетального риска лекарственных средств и фармакоэпидемиологические исследования репродуктивной безопасности. Вопросы гинекологии, акушерства и перинатологии. 2013; 12 (2): 52–60.; Artama M., Gissler M., Malm H., Ritvanen A. Nationwide register-based surveillance system on drugs and pregnancy in Finland 1996–2006. Pharmacoepidemiol Drug Saf. 2011; 20: 729–738.; Erdeljic V., FranceticI., Makar-Ausperger K. et al. Clinical pharmacology consultation: a better answer to safety issues of drug therapy during pregnancy? Eur J ClinPharmacol. 2010; 66: 1037–1046.; Uhl K., Trontell A., Kennedy D. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools. Pharmacoepidemiol Drug Saf. 2007; 16: 337–348.; Macklin R. Enrolling pregnant women in biomedical research. Lancet. 2010; 375: 631–633.; Haas D. M., Gallauresi B., Shields K. et al. Pharmacotherapy and pregnancy: highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy. Clin Transl Sci. 2011; 4: 204–209.; Randy L. Jirtle. PhD: epigenetics a window on gene dysregulation, disease. Interview by Bridget M. Kuehn. JAMA. 2008; 299: 1249–1250.; Chauvenet M., Rimailho A., Hoog-Labouret N. Methodology for the evaluation of drugs in pregnant women. Therapie. 2003; 58: 247–258.; Anger G. J., Piquette-Miller M. Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther. 2008; 83: 184–187.; Coverdale J. H., McCullough L. B., Chervenak F. A. The ethics of randomized placebo-controlled trials of antidepressants with pregnant women: a systematic review. Obstet Gynecol. 2008; 112: 1361–1368.; Baylis F., Kaposy C. Wanted: Inclusive guidelines for research involving pregnant women. J Obstet Gynaecol Can. 2010; 32: 473–476.; Chambers C. D., Polifka J. E., Friedman J. M. Drug safety in pregnant women and their babies: ignorance not bliss. Clin Pharmacol Ther. 2008; 83: 181–183.; Little M. O., Lyerly A. D., Faden R. R. Pregnant women & medical research: a moral imperative. Bioethica Forum. 2009; 2: 60–65.; Rodger M. A., Makropoulos D., Walker M. et al. Participation of pregnant women in clinical trials: Will they participate and why? Am J Perinatol. 2003; 20: 69–76.; Решетько О. В., Луцевич К. А. Клиническая фармакология как методология для улучшения здоровья женщин в XXI в.: путь к персонализированной медицине. Ремедиум. 2012; 7: 57–61.; Rayburn W., Anderson J., Smith C. V. et al. Uterine and fetal Doppler flow changes from a single dose of long-acting intranasal decongestant. Obstet Gynecol. 1990; 76: 180–182.; Herring C., McManus A., Weeks A. Off-label prescribing during pregnancy in the UK: an analysis of 18,000 prescriptions in Liverpool Women’s Hospital. Int J Pharm Pract. 2010; 18: 226–229.; Baird K. L. The new NIH and FDA medical research policies: targeting gender, promoting justice. J Health Polit Policy Law. 1999; 24: 531–565.; https://www.pedpharma.ru/jour/article/view/115

Availability: https://www.pedpharma.ru/jour/article/view/115
https://doi.org/10.15690/pf.v11i2.953

View record from BASE

4

Academic Journal